News & Analysis as of

Personalized Medicine Healthcare

Knobbe Martens

The FDA Approves Two New Gene Therapies for the Treatment of Sickle Cell Disease

Knobbe Martens on

On December 8, 2023, the U.S. Food and Drug Administration (FDA) approved two new gene therapies for the treatment of sickle cell disease. The first, Casgevy™ (exagamglogene autotemcel (exa-cel)), is the first-ever approved...more

Dinsmore & Shohl LLP

Medical Marijuana Will Soon be Legal in Kentucky

Dinsmore & Shohl LLP on

On March 31, 2023, Governor Andy Beshear signed Senate Bill 47 making medical marijuana use and sale legal in Kentucky, effective January 1, 2025. Kentucky now joins at least 37 other states that have legalized medical...more

Foley & Lardner LLP

The Health AI Frontier: New Opportunities for Innovation Across the Health Care Sector

Foley & Lardner LLP on

With the health care industry under pressure to improve patient outcomes while controlling costs, artificial intelligence (AI) and machine learning (ML) are quickly becoming indispensable tools. These technologies show...more

Foley & Lardner LLP

Personalized Medicine Coalition Releases Spring 2020 Newsletter Amid the Coronavirus

Foley & Lardner LLP on

...The Personalized Medicine Coalition (“PMC”) recently published its 2020 Spring Newsletter that examines the landscape and outlook for personalized medicine as COVID-19 prompts new discussions about the effect of COVID-19...more

White and Williams LLP

Digital Twin Technology in Healthcare

White and Williams LLP on

Imagine a future where personalized healthcare will provide every individual with the right treatment at the right time. Advances in precision medicine have already led to powerful new discoveries and treatments that are...more

Foley & Lardner LLP

Precision Medicine - Obama’s Health Care Legacy

Foley & Lardner LLP on

As we come to the end of President Obama’s administration, it is time to look back on the past eight years and the administration’s impact on the delivery of the nation’s health care. While the Affordable Care Act (signed...more

Obermayer Rebmann Maxwell & Hippel LLP

Looking Ahead to 2016 and Beyond: Could the Precision Medical Initiative Revolutionize the Way Patients Receive Medical Treatment?

The Precision Medicine Initiative (“PMI”) was officially unveiled in President Obama’s January 2015 State of the Union address. Precision medicine is an emerging approach for disease prevention and treatment that considers an...more

Foley & Lardner LLP

Three Pressing Challenges for Personalized Medicine

Foley & Lardner LLP on

Personalized medicine can be described as the science of targeted therapies. Advances in diagnostic and molecular medicine have made it possible to more precisely identify alternative treatment options for patients based on...more

Foley & Lardner LLP

Navigating the Diagnostic Commercialization Process

Foley & Lardner LLP on

Guest Post By: Perry Dimas, Senior Vice President and General Manager for Premier Source, part of AmerisourceBergen The 2015 Business of Personalized Medicine Summit was an inspiring day with talented professionals. One...more

Foley & Lardner LLP

Highlights from the Tenth CEO/Innovators Roundtable: June 4 – 5, 2015

Foley & Lardner LLP on

This past June, leaders from health systems, outpatient services companies, health insurers, IT and equipment suppliers, health retailers, home care providers, pharmaceutical companies, and investors gathered in Chicago for...more

Foley & Lardner LLP

Precision Medicine - Even Medicare Will Pay for It!

Foley & Lardner LLP on

President Barack Obama announced in his 2015 State of the Union address that he was introducing a new Precision Medicine Initiative, supported with over $200 million in the proposed 2016 federal budget. "Precision Medicine"...more

Foley & Lardner LLP

AmerisourceBergen Guest Post: Solutions to Overcome Reimbursement Challenges in Personalized Medicine

Foley & Lardner LLP on

The continued development and refinement of personalized medicine (PM) has offered an opportunity to revolutionize medical practice and improve outcomes by providing treatments for patients with the notion that “this drug is...more

Wilson Sonsini Goodrich & Rosati

The Life Sciences Report - Spring 2015

In This Issue: - The Rise of Companion Diagnostics in Personalized Medicine: Challenges and Opportunities - Department of Justice Imposes More Than $110 Million in Fines on Medical Device Makers - Life...more

Foley & Lardner LLP

Will Personalized Medicine Survive Alternative Payment Models?

Foley & Lardner LLP on

There is no doubt that health care costs in the United States are rising. According to a recent study published by the U.S. Department of Health and Human Services, personal health care expenditures in the United States...more

Foley & Lardner LLP

An Update on 21st Century Cures Legislation

Foley & Lardner LLP on

Last week the Personalized Medicine Coalition held its 11th Annual State of Personalized Medicine luncheon in Washington, D.C. U.S. Representative Michael Burgess, a member of the House Energy and Commerce Committee...more

Faegre Drinker Biddle & Reath LLP

The Double-Edged Sword: Genomic Profiling in Drug and Chemical Litigation

Since completion of the Human Genome Project, genomic profiling and the related advent of personalized medicine have become a hot topic. Many predicted this new genomic information would lead to targeted drug treatments that...more

McGuireWoods LLP

Washington Healthcare Update

McGuireWoods LLP on

This Week: House E&C Releases Discussion Draft of 21st Century Cures Legislation Ahead of Legislative Hearing... FDA Finalizes Biosimilar Guidance Documents... CMS Updates Wage Index and Payment Rates for the Medicare Hospice...more

Foley & Lardner LLP

California's Bet on Precision Medicine

Foley & Lardner LLP on

California sees opportunities in personalized medicine. Earlier this month, Governor Brown announced the creation of a two year initiative – California Initiative to Advance Precision Medicine to “begin building...more

Foley & Lardner LLP

Waiting on Sequenom

Foley & Lardner LLP on

As I write this there’s a voice in my head saying, “Be careful what you wish for!” but it has been five months since Sequenom was argued at the Federal Circuit, and the court has yet to issue its decision. In the meantime,...more

Foley & Lardner LLP

Perspectives on the President’s Precision Medicine Initiative

Foley & Lardner LLP on

President Obama’s “precision medicine initiative” earmarked over $200 million from his proposed 2016 budget to “bring us closer to curing diseases like cancer and diabetes – and to give all of us access to the personalized...more

Foley & Lardner LLP

What Does President Obama's $215 Million "Precision Medicine Initiative" Mean for Genetic Privacy?

Foley & Lardner LLP on

We have all heard about the burgeoning opportunities tied to the development of precision medicine (also called “personalized medicine”), which includes the use of an individual’s genetic information to design targeted...more

Foley & Lardner LLP

Details Emerge for President’s Precision Medicine Initiative

Foley & Lardner LLP on

Personalized medicine has a friend in high places. President Obama recently announced an initiative to support “precision” or personalized medicine. In very general terms, the President stated during his 2015 State of the...more

Foley & Lardner LLP

President Obama Revisits Interest in Personalized Medicine

Foley & Lardner LLP on

President Obama announced during his 2015 State of the Union Address that he is launching a new “precision” or personalized medicine initiative to advance personalized, effective therapies for the American public. As reported...more

McGuireWoods LLP

Healthcare & Life Sciences Private Equity Deal Tracker: Assurex Health Secures $30 Million in Financing

McGuireWoods LLP on

Assurex, headquartered in Mason, Ohio, is a personalized medicine company specializing in helping physicians determine the right medication for individual patients with behavioral health disorders....more

Foley & Lardner LLP

Another Patent Challenge for Personalized Medicine

Foley & Lardner LLP on

The U.S. Supreme Court’s recent trilogy of patent-eligibility decisions (Prometheus, Myriad and Alice) have called into question the validity of many U.S. patents on diagnostic medical methods. Nevertheless, legal battles...more

40 Results
 / 
View per page
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide